Five year results from the ponatinib phase 2 PACE trial has shown that this 3rd generation TKI is effective in treating patients with relapsed or intolerant CML, Philadelphia chromosome positive ALL, or malignancies with BCR-ABL T351I [31]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.